| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF5 |
| Uniprot No | P55010 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-431aa |
| 氨基酸序列 | MSVNVNRSVSDQFYRYKMPRLIAKVEGKGNGIKTVIVNMVDVAKALNRPPTYPTKYFGCELGAQTQFDVKNDRYIVNGSHEANKLQDMLDGFIKKFVLCPECENPETDLHVNPKKQTIGNSCKACGYRGMLDTHHKLCTFILKNPPENSDSGTGKKEKEKKNRKGKDKENGSVSSSETPPPPPPPNEINPPPHTMEEEEDDDWGEDTTEEAQRRRMDEISDHAKVLTLSDDLERTIEERVNILFDFVKKKKEEGVIDSSDKEIVAEAERLDVKAMGPLVLTEVLFNEKIREQIKKYRRHFLRFCHNNKKAQRYLLHGLECVVAMHQAQLISKIPHILKEMYDADLLEEEVIISWSEKASKKYVSKELAKEIRVKAEPFIKWLKEAEEESSGGEEEDEDENIEVVYSKAASVPKVETVKSDNKDDDIDIDAI |
| 预测分子量 | 65.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF5重组蛋白的3篇参考文献示例(文献为假设性示例，仅供参考)：
---
1. **文献名称**：*Structural and Functional Analysis of Recombinant EIF5 in Translation Initiation*
**作者**：Chen L, et al.
**摘要**：通过重组表达纯化EIF5蛋白，结合冷冻电镜技术解析其三维结构，揭示了EIF5与40S核糖体及起始因子复合物相互作用的分子机制，证实其在起始密码子选择中的关键作用。
2. **文献名称**：*EIF5 Overexpression Drives Oncogenic Signaling in Breast Cancer Cells*
**作者**：Wang Y, et al.
**摘要**：研究利用重组EIF5蛋白在乳腺癌细胞中过表达，发现其通过激活mTOR通路促进肿瘤细胞增殖和迁移，提示EIF5作为潜在治疗靶点。
3. **文献名称**：*Kinetic Characterization of Recombinant EIF5 in GTP Hydrolysis*
**作者**：Smith RJ, et al.
**摘要**：通过体外酶学实验分析重组EIF5的GTP酶活性，证明其依赖eIF2β亚基的协同作用，为翻译起始的调控机制提供了动力学依据。
---
**备注**：以上文献为示例，实际引用时需查询真实数据库(如PubMed、Web of Science)获取准确信息。若需具体文献协助，可进一步提供研究方向或关键词优化检索。
**Background of EIF5 Recombinant Protein**
Eukaryotic translation initiation factor 5 (EIF5) is a critical regulatory protein involved in the initiation phase of protein synthesis. It functions as a GTPase-activating protein (GAP) for the eukaryotic initiation factor 2 (eIF2), facilitating the hydrolysis of GTP bound to eIF2 during the assembly of the 80S ribosome. This step is essential for the recognition of the start codon and the transition from initiation to elongation in translation. EIF5 interacts with other initiation factors, such as eIF2 and eIF3. forming a dynamic network that ensures accurate and efficient translation initiation.
Structurally, EIF5 contains distinct domains, including an N-terminal RNA-binding region and a C-terminal catalytic domain responsible for its GAP activity. Dysregulation of EIF5 has been linked to various diseases, including cancers and neurodegenerative disorders, underscoring its importance in cellular homeostasis.
Recombinant EIF5 protein is produced using expression systems like *E. coli* or mammalian cell cultures, enabling high-purity, functional studies. Its recombinant form allows researchers to investigate mechanistic details of translation initiation, screen for inhibitors or modulators in drug discovery, and explore its role in disease pathways. Studies utilizing recombinant EIF5 have provided insights into mutations affecting translation fidelity and potential therapeutic targets. Overall, EIF5 remains a pivotal molecule in understanding translational control and its implications in health and disease.
×
